Capstone Therapeutics Corp. (CAPS)
USD 2.08
(-11.49%)
USD 2.08
(-11.49%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 9.61 Million USD | -41.86% |
| 2022 | 16.53 Million USD | 1.32% |
| 2021 | 16.31 Million USD | 49.2% |
| 2020 | 10.93 Million USD | 28141.03% |
| 2019 | -39 Thousand USD | 75.16% |
| 2018 | -157 Thousand USD | 23.41% |
| 2017 | -205 Thousand USD | -14.53% |
| 2016 | -179 Thousand USD | -14.01% |
| 2015 | -157 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.78 Million USD | 61.79% |
| 2024 Q1 | 1.72 Million USD | 40.46% |
| 2023 Q1 | 2.39 Million USD | -17.23% |
| 2023 Q3 | 2.51 Million USD | -27.79% |
| 2023 Q2 | 3.48 Million USD | 45.48% |
| 2023 FY | 9.61 Million USD | -41.86% |
| 2023 Q4 | 1.22 Million USD | -51.21% |
| 2022 Q1 | 3.4 Million USD | -8.36% |
| 2022 Q4 | 2.89 Million USD | -40.9% |
| 2022 Q3 | 4.89 Million USD | -8.62% |
| 2022 FY | 16.53 Million USD | 1.32% |
| 2022 Q2 | 5.35 Million USD | 57.38% |
| 2021 Q1 | 1.54 Million USD | -52.87% |
| 2021 Q4 | 3.71 Million USD | -35.55% |
| 2021 Q3 | 5.75 Million USD | 8.52% |
| 2021 FY | 16.31 Million USD | 49.2% |
| 2021 Q2 | 5.3 Million USD | 243.08% |
| 2020 FY | 10.93 Million USD | 28141.03% |
| 2020 Q3 | 4.28 Million USD | 0.0% |
| 2020 Q4 | 3.28 Million USD | -23.47% |
| 2019 FY | -39 Thousand USD | 75.16% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 Q2 | 1.74 Million USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | -100.0% |
| 2018 FY | -157 Thousand USD | 23.41% |
| 2018 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | -205 Thousand USD | -14.53% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | -179 Thousand USD | -14.01% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | -157 Thousand USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 394154.941% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 17.897% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 3108.072% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 91.931% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 137.255% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 20015.456% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 7835.149% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 35.922% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -309732.366% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 1.868% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -14522.383% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 28243.485% |
| Mesoblast Limited | -35.16 Million USD | 127.329% |
| Marizyme, Inc. | 457.7 Thousand USD | -1999.838% |
| Genus plc | 178.7 Million USD | 94.622% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 95.633% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -15345.312% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -2243.203% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 87472.727% |
| ContraFect Corporation | -154 Thousand USD | 6340.909% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 19322.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -12420.681% |
| IMV Inc. | -962.29 Thousand USD | 1098.755% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 2580.252% |
| MultiCell Technologies, Inc. | 49.32 USD | -19486923.52% |
| ONE Bio Corp. | 20.12 Million USD | 52.245% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 76.131% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -19554.397% |
| Q BioMed Inc. | -8988.00 USD | 107031.464% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 65.985% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 62411.981% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 78.333% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 941.909% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -13630.0% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 194183.199% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -6740.569% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 9955.92% |
| GB Sciences, Inc. | -624.00 USD | 1540324.359% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 11271.944% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.873% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 4620773.077% |
| Enzolytics Inc. | 30.7 Thousand USD | -31198.033% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -1892.194% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.133% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 1967.991% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -1456.73% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 97.653% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 108625.294% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 11562.271% |
| Kadimastem Ltd | -630.13 Thousand USD | 1625.221% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -872.792% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 37.691% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 81308.281% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -5343.475% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -5343.475% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -608.179% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 33241.379% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -2035.574% |
| SYBLEU INC | 11.69 Thousand USD | -82073.393% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -108.572% |
| Bioxytran, Inc. | -8285.00 USD | 116104.828% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 2676.676% |
| Neutra Corp. | 14.33 Thousand USD | -66945.692% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 11820.732% |
| PureTech Health plc | -1.6 Million USD | 699.563% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 1059.914% |
| IXICO plc | 3.27 Million USD | -193.914% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 1484.87% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 636.628% |
| CSL Limited | 7.7 Billion USD | 99.875% |
| Cellectis S.A. | 18 Thousand USD | -53294.444% |